Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa
  • Amsterdam
  • Berlin
  • Brussels
  • Copenhagen
  • Danske Bank
  • Denmark
  • DFDS
  • DSV
  • Faroe Islands
  • Greenland
  • Helsinki
  • LEGO
  • Mærsk
  • Novo Nordisk
  • Ørsted
  • Oslo
  • Riga
  • Stockholm
  • Tallinn
  • Vestas Wind Systems
  • Vilnius
  • Warsaw
Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa

Browsing Tag

Lexicon Pharmaceuticals

11 posts
NNovo Nordisk
Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone
Read More

Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone

  • 2026-08-25
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
NNovo Nordisk
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
Read More

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon

  • 2026-08-24
Novo began the early-stage study in March 2026. Results from the trial are due in early 2027. Lexicon’s…
NNovo Nordisk
In this photo illustration, the Lexicon Pharmaceuticals logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)
Read More

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon

  • 2026-08-24
Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.…
NNovo Nordisk
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Read More

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

  • 2026-08-24
Lexicon Pharmaceuticals, Inc. LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment…
NNovo Nordisk
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones
Read More

Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones

  • 2026-05-10
​Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy right now. On…
NNovo Nordisk
Lexicon Q1 revenue hits $21.1M, cash rises to $199.7M
Read More

Lexicon Q1 revenue hits $21.1M, cash rises to $199.7M

  • 2026-05-07
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported Q1 2026 results and pipeline updates on May…
NNovo Nordisk
Novo Nordisk Rare Disease Wins Add Context To Undervalued Share Price
Read More

Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 Trial

  • 2026-05-04
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
NNovo Nordisk
Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851
Read More

Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851

  • 2026-05-01
​Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best biotech penny stocks to buy in 2026. On March…
NNovo Nordisk
Lexicon earns $10M as Novo starts LX9851 Phase 1
Read More

Lexicon earns $10M as Novo starts LX9851 Phase 1

  • 2026-03-25
Lexicon Pharmaceuticals (Nasdaq: LXRX) and Novo Nordisk announced initiation of a Phase 1…
NNovo Nordisk
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Read More

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

  • 2026-03-24
Lexicon Pharmaceuticals, Inc. LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment…
NNovo Nordisk
Novo Nordisk Confronts Hims Over Wegovy Pill Copies And GLP 1 Future
Read More

Novo Nordisk (CPSE:NOVO B) Valuation Check As LX9851 Expands Its Obesity Drug Pipeline

  • 2026-03-23
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…
Denmark
www.europesays.com